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CC BY-NC-ND license (http://creativeAbstract One of the greatest obstacles to current cancer treatment efforts is the develop-
ment of drug resistance by tumors. Despite recent advances in diagnostic practices and surgi-
cal interventions, many neoplasms demonstrate poor response to adjuvant or neoadjuvant
radiation and chemotherapy. As a result, the prognosis for many patients afflicted with these
aggressive cancers remains bleak. The insulin-like growth factor (IGF) signaling axis has been
shown to play critical role in the development and progression of various tumors. Many basic
science and translational studies have shown that IGF pathway modulators can have promising
effects when used to treat various malignancies. There also exists a substantial body of recent
evidence implicating IGF signaling dysregulation in the dwindling response of tumors to current
standard-of-care therapy. By better understanding both the IGF-dependent and -independent
mechanisms by which pathway members can influence drug sensitivity, we can eventually aim
to use modulators of IGF signaling to augment the effects of current therapy. This review702 6216; fax: þ1 773 702 4765.
.edu (H.H. Luu).
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14 S.K. Denduluri et al.summarizes and synthesizes numerous recent investigations looking at the role of the IGF
pathway in drug resistance. We offer a brief overview of IGF signaling and its general role in
neoplasia, and then delve into detail about the many types of human cancer that have been
shown to have IGF pathway involvement in resistance and/or sensitization to therapy. Ulti-
mately, our hope is that such a compilation of evidence will compel investigators to carry
out much needed studies looking at combination treatment with IGF signaling modulators to
overcome current therapy resistance.
Copyright ª 2014, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).Introduction
The insulin-like growth factor (IGF) signaling axis is critical
to the growth, development, and maintenance of many
tissues within the human body.1 It is particularly important
during neonatal and pubertal growth, and essentially
carries out its effects by simulating cell proliferation and
interrupting programmed cell death.1,2 The IGF system is
comprised of two ligands, IGF-1 and IGF-2, which exhibit
their effects through binding to IGF-1R (primarily), IGF-2R,
and the insulin receptor (IR), all belonging to the tyrosine
kinase receptor family.1
Upon binding the IGF ligand, IGF-1R is activated through
autophosporylation, and subsequently phosphorylates in-
sulin receptor substrate 1 (IRS-1).2 Activated phosphoino-
sitide 3-kinase (PI3K) then leads to increased
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which re-
sults in the activation of the critical protein AKT/PKB (AKT
for short) through phosphorylation.3 AKT then performs a
variety of functions, such as releasing the anti-apoptotic
protein Bcl-2 from Bad, activating protein synthesis
through mTOR, and promoting glucose metabolism by
inhibiting GSK-3b.3,4 This is commonly referred to as the
PI3K/AKT pathway of IGF-1R signaling and is ultimately
responsible for preventing cell death (Fig. 1).5
In parallel, IGF-1R signaling also promotes cell differ-
entiation proliferation via the Ras/MAPK pathway
(Fig. 1).3 IGF-1R activates the IRS protein SHC, which then
stimulates Raf through the GTPase Ras. Raf then triggers a
kinase cascade eventually resulting in the activation of
mitogen-activated protein kinases (MAPKs), ERK1 and
ERK2. These MAPKs go on to phosphorylate and activate
several targets, notably the transcription factor ELK1
which promotes gene expression and therefore cell
growth.3,6,7
The activity of the IGF ligands and receptors is modu-
lated in a complex fashion by six IGF binding proteins
(IGFBPs), named IGFBP-1 through IGFBP-6, respectively.
The IGFBPs are usually bound directly to IGF-1 (or IGF-2) in
extracellular fluids, serving to mediate the half-life and
localized availability of the ligands in circulation.8
Furthermore, extensive evidence has recently elucidated
that the IGFBPs have many IGF-independent actions. By
associating directly with many extracellular and cell-
surface markers, these binding proteins are able to cause
a variety of unique effects involving growth and
differentiation.8Taken as a whole, the IGF signaling axis has vast impli-
cations for cellular proliferation, apoptosis, and in-
teractions with the microenvironment. Though these
processes are critical for normal development and main-
tenance of tissues, it has also become increasingly evident
that dysregulation of this pathway contributes significantly
to abnormal growth and disease states.IGF signaling in cancer and the development of
drug resistance
Numerous cancers have been shown to be associated with
aberrant IGF signaling, including colon cancer, prostate
cancer, pancreatic cancer, melanoma, osteosarcoma, and
childhood malignancies, among many others.9 Numerous
in vitro, in vivo, and clinical studies have shown that
increased IGF-1R activity is implicated in cancer cell pro-
liferation, migration, and invasion.9,10 IGF ligand appears to
be delivered not only from distant sources (i.e. endocrine
signaling), but also through paracrine/autocrine signaling in
more aggressive tumors.10 In addition, increased serum
levels of IGF-1 have been observed in cancers of the lung,
colon, prostate, and breast.11e14 Many other IGF pathway
members are also thought to play a role in malignancies.
From increased circulating levels of IGF-2 in colorectal
cancer to suppressed activity of IGFBP-5 in osteosarcoma, it
is clear that the IGF axis serves as an important lens to
better understand and address the underlying mechanisms
of neoplasia.15e17 In fact, several IGF signaling modulators
have undergone significant basic science and translational
investigations with promising results; currently, monoclonal
antibodies to IGF-1R are undergoing clinical trials.18 How-
ever, it has become clear that the IGF axis is part of a much
larger network of cellular signaling that ultimately results
in the highly proliferative and invasive cancer
phenotypes.19
Current non-surgical forms of cancer treatment are
largely limited by severe systemic side effects and acquired
resistance, resulting in increased morbidity and decreased
survival. Of the many processes that are thought to play a
role in the resistance of neoplasms to radiation or chemo-
therapy, the IGF signaling axis has been recurrently deemed
as a culprit.20 Here, we review recent literature implicating
IGF signaling in resistance to therapy among various types
of human cancer. With a better grasp of the underlying
mechanisms, we can one day hope to augment the efficacy
Figure 1 Schematic of IGF signaling and major downstream effects. Activation of IGF-1R can result in signaling via two pathways:
PI3K/AKT and Ras/MAPK. PI3K/AKT results in decreased apoptosis, increased protein synthesis, and increased glucose metabolism,
among various other effects not represented here. Ras/MAPK contains an elaborate kinase cascade that ultimately leads to
increased cellular proliferation by promoting the activity of transcription factors, such as ELK1. The activity of IGF ligands is
modulated by IGFBPs through direct binding in the extracellular space. IGFBPs also exert several IGF-independent effects via direct
interaction with cell membrane-bound proteins, such as integrins.
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signaling axis.Breast cancer
Breast cancer is one of the most prevalent diseases in the
world, and considered to be the most invasive cancer in
women. Though there have been significant technological
and public health improvements leading to early detection
and surgical removal of tumors, disease-free survival re-
mains limited due to drug resistance.21 Of the various
mechanisms that are thought to contribute to this, IGF
signaling has recently been implicated as a crucial factor.
In estrogen receptor positive (ERþ) breast cancer, there
appears to be a link between IGF-1R and progression of
disease despite anti-estrogen therapy. In fact, IGF-1R is
upregulated in cancer cells that are resistant to tamoxifen,
an estrogen antagonist in breast tissue.22 This is thought to
be due to crosstalk between IGF-1R and ER, as well as
MAPK/ERK and PI3K/AKT signaling downstream of IGF
signaling.23,24 One study looked at ERþ breast cancer cells
resistant to long-term estrogen deprivation, showing that
AKT inhibition led to compensatory upregulation of IGF-1R/
IR and IGF ligands, but that simultaneous blockade of IGF-
1R/IR enhanced the anti-tumor effects of AKTinhibition.25 Furthermore, variations in IGF-1R structure
and function correlate with anti-estrogen resistance. In a
study of 222 British patients with ERþ invasive breast
cancer treated with tamoxifen, a polymorphism of the IGF-
1R gene was found to have significantly increased risk for
tumor progression (hazard ratio [HR] 2.04) and death (HR
1.84). Other polymorphisms were also found to be signifi-
cantly associated with tumor size and lymph node
involvement.26 Finally, the activity of IGFBPs is also impli-
cated, but in an IGF-independent manner. For example,
IGFBP-3 appears to sensitize ERþ breast cancer cells to the
anti-estrogen fulvestrant by inhibiting anti-apoptotic ef-
fects of GRP78, a binding partner of the caspase 7
complex.27
Another prevalent form of breast cancer is HER2 re-
ceptor positive (HER2þ), and drugs that work by targeting
this marker have also met with significant tumor resistance.
Trastuzumab (Herceptin) is a monoclonal antibody to HER2
that is commonly used in therapy, but limited drug efficacy
appears to be, in large part, due to IGF signaling. In models
of breast cancer cells that overexpress HER2, trastuzumab
activity is disrupted by increased expression of IGF-1R.28
Furthermore, upregulation of IGF-1R by epigenetic
silencing of microRNA 375 partially leads to a trastuzumab-
resistant phenotype, while overexpression of microRNA 375
restores sensitivity of HER2þ cells to the drug.29
16 S.K. Denduluri et al.Immunohistochemistry supports that overexpression of IGF-
1R and epidermal growth factor 1-receptor (EGFR), and/or
dysregulation of the downstream PI3K/AKT pathway can
also confer this trastuzumab resistance in a subset of pa-
tients found to have metastases.30
It is clear that IGF signaling has significant implications
for treatment and survival of breast cancer patients. This
has led many to believe that co-targeting IGF-1R and well-
known breast cancer cell receptors (e.g. ER, HER2) may
circumvent drug resistance.31,32 However, several in-
vestigations indicate that the solution may not be so
straightforward. A recent study using estrogen-resistant
ERþ breast cancer cells demonstrated that dual treat-
ment with fulvestrant and dasatinib, a nonspecific tyrosine
kinase inhibitor, had superior outcomes when compared to
combination fulvestrant and IGF-1R monoclonal antibody
therapy.33 This may be due to fact that tyrosine-kinases in
general are upregulated in endocrine therapy-resistant
breast tumors. Moreover, another study showed that ERþ
cancer cells selected for tamoxifen resistance in vitro may
actually have decreased IGF-1R expression and therefore
less responsiveness to monoclonal antibodies directed
against just this receptor.34 The incongruence of these re-
sults with those of studies mentioned previously in this
review may ultimately be due to methodology, but high-
lights the notion that growth factor and hormone signaling
in neoplasms is incredibly complex. Nonetheless, the IGF
signaling axis remains an intriguing entity in breast cancer
and drug resistance.Ovarian cancer
Ovarian cancer is one of the deadliest diseases in women,
with diagnosis usually made after the onset of symptoms
and when metastases are already present.35 In addition,
significant drug resistance has been reported to current
chemotherapy regimens, which is particularly devastating
to those patients who may not be candidates for surgical
intervention.36 Similar to its implications in breast cancer,
the IGF signaling pathway appears to also play a role in
ovarian cancer drug resistance. In A2780 ovarian carcinoma
cells treated with either cisplatin or cisplatin and taxol
in vitro, early stages of drug resistance are correlated with
upregulation of IGF-1R. Furthermore, primary tumors har-
vested from patients after 3e4 cycles of platinum-taxol
treatment also demonstrate increased IGF-1R expres-
sion.37 A gene microarray study of 28 patients with high-
grade serous ovarian cancer demonstrated that samples
relatively resistant to platinum chemotherapy showed
enrichment of genes involving IGF1/PI3K/NFkB/ERK
signaling when compared to those tumors remaining sensi-
tive to treatment.38 This finding, replicated in several
studies, is thought to be the result of two distinct mecha-
nisms beyond just IGF-1R upregulation, including loss of the
tumor suppressor PTEN and IGF-2 overexpression.39
Interestingly, IGF-2 is thought to be more closely asso-
ciated with ovarian cancer drug resistance, despite being
less prevalent than IGF-1 in signaling. An analysis of serous
ovarian cancer patients using The Cancer Genome Atlas
demonstrated that higher IGF-2 mRNA expression was
correlated with indicators of drug resistance, including ashorter time to disease progression and death.40 In addi-
tion, transient knockdown of IGF-2 using short-hairpin RNA
restores taxol sensitivity in a xenograft model of serous
papillary ovarian carcinoma.40 Other studies have also
demonstrated efficacy by inhibiting this pathway. Ganitu-
mab, a human monoclonal antibody to IGF-1R, can augment
the response to platinum-based chemotherapy by inhibiting
IGF-2-dependent ovarian cancer growth.39 However,
blockade of IGF-1R does not seem to counteract taxol
resistance.40 This may be explained by the fact that
cisplatin and taxol resistance may not arise from the same
signaling mechanisms, though members of the IGF pathway
appear to be critically involved in both cases. As in breast
cancer, the IGF signaling axis represents a target for much
needed effective therapy in ovarian cancer.Prostate cancer
Prostate cancer remains one of the leading concerns in
men’s health, accounting for about 15% of all new cancer
cases in the U.S. every year. When distant mestastases are
present, the 5-year relative survival is only 28% when
compared to localized disease, making pharmacologic
therapy all the more critical in these patients.41 In patients
with disseminated disease, androgen deprivation therapy
(ADT) is the standard approach and can be accomplished
either surgically through bilateral orchiectomy or medically
using a continuous gonadotropin releasing hormone (GnRH)
agonist. Tumors that respond to this therapy are referred to
as castration sensitive, though there are an alarming
number of cases that become castration resistant (or
androgen independent [AI]) [need citation].
As in other neoplasms, IGF-1R has been extensively
implicated in the progression of prostate cancer, particu-
larly through contributing to the development of AI disease.
There has been considerable research into the interactions
between IGF-1R and the androgen receptor (AR).42 Nor-
mally, AR binds to an androgen ligand and is subsequently
translocated from the cytoplasm to the nucleus of cells,
where it serves as a transcription factor and promotes tis-
sue growth.43 In the absence of androgen ligand, as is the
case with ADT in prostate cancer, an inactive AR remains in
the cytosol.44 However, it appears that in certain cases IGF
signaling actually can actually drive translocation of AR into
the nucleus, even in the absence of androgen.42 This pre-
sents a potential mechanism by which prostate cancer can
progress to AI disease, especially if IGF signaling is upre-
gulated. Furthermore, studies show that inhibiting IGF-1R
using an antibody can prevent this transactivation of AR,
establishing a potential therapy for prostate cancer pro-
gression despite castration.42
It appears that IGFBPs also have significant roles in
driving prostate cancer development. IGFBP-1 is known to
upregulate IGF-1 activity by modulating serum concentra-
tions and tissue delivery of the ligand. Thus, it follows that
in patients with metastatic disease undergoing ADT,
increased levels of IGFBP-1 are associated with a shorter
interval to castration resistance, and consequently,
decreased survival.45 In vivo studies also show that deleting
IGFBP-1 in mice actually decreases growth of prostate tu-
mors, perhaps by activating a5b1 integrin in an IGF-
IGF signaling in cancer drug resistance 17independent manner.46,47 There has also been significant
research looking at the link between insulin-resistance/
diabetes and prostate cancer, with IGFPB-2 being recently
implicated in this phenomenon. In docetaxel-treated
prostate cancer cell lines, hyperglycemia significantly re-
duces drug-induced apoptosis through glucose-mediated
upregulation of IGFBP-2. Knocking out IGFBP-2, on the
other hand, reverses the survival effect caused by hyper-
glycemia.48 Finally, IGFBP-related proteins (IGFBP-rPs),
similar in structure and function to IGFBPs but with weaker
affinity for IGF ligands, can play a role in reversing prostate
cancer resistance. Restoring IGFBP-rP1 activity has been
found to increase both chemosensitivity to docetaxel and
radiosensitivity of prostate cancer cells in vitro.49 Ulti-
mately, it is evident that a better understanding of various
members of the IGF signaling axis can help lead to more
effective treatment of drug-resistant prostate cancer.Lung cancer
Lung cancer is one of the most devastating human diseases,
accounting for more than a quarter of all cancer deaths.50
At the time of diagnosis, many patients do not qualify for
surgical intervention, and those who are able to have the
primary tumor resected still remain susceptible to disease
progression and distant metastasis due to drug resistance.51
Again, the IGF signaling pathway appears to be implicated
in this resistance, and targeting it presents a potential
approach to lung cancer treatment moving forward. Gefi-
tinib, an epidermal growth factor receptor (EGFR)-specific
tyrosine kinase inhibitor (TKI), is one of the most commonly
used drugs for non-small cell lung cancer (NSCLC). Many
studies have demonstrated decreased response of NSCLC
tumors and cell lines to gefitinib, and IGF-1R appears to be
a marker associated with this resistance. Essentially, it
appears as though IGF signaling is upregulated as a means of
compensating for the EGFR blockade, in part contributing
to a drug-resistant phenotype.
One study found that the activity of IGF-1R predicts
resistance of NSCLC to gefitinib, though it may not actually
play a role in development of drug resistance itself. That is,
cell lines that were already resistant to gefitinib were found
to have increased total-IGF-1R and phosphorylated-IGF-1R
expression, but overexpression of IGF-1R did not confer
resistance to gefitinib-sensitive cells.52 Another study
looking at IGF-1R expression using immunohistochemistry
did not find any association between IGF-1R activity and
clinical outcomes of gefitinib-treated NSCLC.53 These
disparate conclusions may ultimately be attributed to the
characteristics of patient samples used in these studies, as
tumor microenvironment appears to contribute heavily to
the molecular properties of cancer cells. For example, in
NSCLC with an activating mutation of EGFR, IGF-1R activity
promotes resistances to gefitinib in lung cancer stem cells
(CSCs) under hypoxic conditions. Furthermore, inhibiting
IGF-1R actually decreases the population of gefitinib-
resistant CSCs in the setting of hypoxia.54 Thus, it is
possible that IGF-1R may indeed drive NSCLC tumor resis-
tance to drugs such as gefitinib, but perhaps only in specific
cell lines and under particular micro-environmental
conditions.Analogous patterns of IGF-1R overexpression in NSCLC
drug resistance have been demonstrated with erlotinib,
another EGFR-TKI.55 Furthermore, in tumors that prefer-
entially respond to erlotinib therapy due to an EGFR-
activating mutation in exon 19, crosstalk between IGF-1R
and epithelial-mesenchymal transition (EMT) signaling can
rapidly confer drug resistance.56 In fact, the median in-
terval between initiation of EGFR-TKI therapy and acquired
resistance is only 6e12 months in patients afflicted by tu-
mors with this common mutation.57,58 Therefore, there is a
significant need to block IGF-1R/EMT crosstalk in patients
that are identified to have this mutation, especially since
their initial response to therapy can be so pronounced.
Regardless of the mechanisms by which EGFR-TKI resis-
tance arises, it seems that IGF-1R inhibition can play a role
in re-sensitizing tumors to drugs. AG1024, which prevents
autophosphorylation of IGF-1R, synergizes with gefitinib to
produce pro-apoptotic and anti-proliferative effects
in vitro in previously gefitinib-resistant NSCLC cells.59 In
mutant KRAS lung adenocarcinoma, IGF’s downstream
PI3K/AKT signaling is thought to be involved with both this
gefitinib resistance and re-sensitization by interacting with
the anti-apoptotic Ku70 and pro-apoptotic BAX proteins.60
The IGFBPs have also been found to play a role in lung
cancer resistance to chemotherapy. Apart from binding to
ligands and mediating direct IGF-1R signaling, the IGFBPs
are known to trigger various independent effects as well.
For example, IGFBP-2 directly interacts with integrins and
the extracellular matrix to stimulate growth.61 IGFBP-2
appears to be causally associated with NSCLC resistance
to dasatinib, a BCR-ABL and SRC family TKI.62,63 Further-
more, focal adhesion kinase (FAK), which is downstream of
IGFBP-2 and integrin binding, is correlated with increased
levels of IGFBP-2 and contributes to the dasatinib-resistant
phenotype. Both in vitro and in vivo, dual inhibition of
IGFBP-2 and FAK reverses NSCLC resistance by restoring
apoptotic sensitivity to dasatinib.63 It stands to reason that
both IGFBP-2 and FAK may be used as biomarkers and
therapeutic targets in patients with NSCLC to predict and
augment response to dasitinib.
Unlike IGFBP-2, IGFBP-3 appears to be inversely corre-
lated with TKI resistance.64 NSCLC lines with acquired
resistance to gefitinib or erlotinib demonstrate decreased
secretion of IGFBP-3 in vitro. However, upon evaluating the
serum of 20 patients, there was no observed difference in
IGFBP-3 levels before and after developing resistance to
EGFR-TKI.65 These disparate conclusions may be explained
by understanding that IGFBP-3 levels are primarily main-
tained by hepatic cells.66 That is, IGFBP-3 may serve as a
marker of resistance on a cellular level in lung cancer, but
this difference is washed out on an organismal level
because the tumor’s contribution to serum levels is pro-
portionally insignificant. Furthermore, it seems that the
protein may not actually be involved in the pathophysiology
of EGFR-TKI resistance. Adenoviral expression or small
interfering RNA (siRNA) suppression of IGFBP-3 does not
alter the response of NSCLC to these drugs.65 Conversely,
IGFBP-3 shows some promise in lung cancer that has
become resistant to cisplatin (CDDP) therapy. In cells
treated with CDDP, promoter methylation decreases
expression of IGFBP-3, thereby driving signaling activity of
the IGF-1R/PI3K/AKT pathway and inducing resistance.67
18 S.K. Denduluri et al.Treating H640 NSCLC cells with recombinant human IGFBP-3
or IGF-1R-inhibiting siRNA can confer sensitivity to
cisplatin, further demonstrating that both of these mem-
bers may belong to the same drug resistance pathway.68
Finally, IGFBP-7 is thought to be a tumor suppressor,
downstream of p53, with implications for treating drug-
resistant lung cancer.69 MAP kinase phosphatase 3 (MKP3)
has been found to reduce expression of IGFBP-7, driving
NSCLC resistance to cisplatin therapy. Furthermore, MKP3
knockdown increases the transcriptional level of IGFBP-7,
which presents a promising approach for sensitizing tu-
mors to cisplatin.70 Ultimately, the IGF signaling axis pre-
sents numerous opportunities for researchers to better
understand and attempt to overcome drug resistance in one
of deadliest forms of cancer.Central Nervous System (CNS) tumors
Glioma comprises about 30% of all CNS tumors, with a
particularly poor prognosis when diagnosed in the brain.71
Surgical resection is often not an option for many pa-
tients, who rely immensely on radio- and chemotherapy. In
these cases, tumors acquire resistance within just a short
interval after beginning therapy.72 In terms of radiation,
cancer stem cells have been though to play a critical role in
tumor progression despite aggressive treatment. Not sur-
prisingly, IGF-1R signaling seems to be involved in glioma
stem cells’ (GSCs) ability to adapt to repeated irradiation.
One study showed that radiation exposure caused an
upregulation of both IGF1 secretion and IGF-1R expression,
leading to downstream AKT survival signaling in GSCs.
Furthermore, treating radioresistant cells with an IGF-1R
inhibitor markedly increases sensitivity to radiation.73
With regards to chemotherapy and glioma, members of
the IGF axis are again thought to contribute to resistance
mechanisms. In GSCs, there appears to exist cooperative
signaling between the Hedgehog (HH) pathway and the IGF
axis that promotes resistance to temozolamide. GLI1, a
transcription factor downstream of HH that targets insulin
receptor substrate 1 (IRS-1), allows for activation of MAPK by
IGF-1 signaling, leading to cell proliferation. Suppressing
GLI1 decreases IGF-1-dependent proliferation, invasion, and
angiogenesis by increasing GSC response to temozolamide.74
Independent of HH, IGF-1-induced activation of PI3K ap-
pears to protect U251 glioma cells from tamoxifen-induced
apoptosis, which can be partially overcome by combina-
tion treatment with a specific PI3K inhibitor (LY294002) or
PI3K subunit P85 siRNA. Furthermore, the effects of
LY294002 appear to be mediated through activation (or
dephosphorylation) of GSK3, which inhibits gene transcrip-
tion by b-catenin.75 Despite this compelling evidence that
IGF signaling contributes to drug resistance, other studies
have muddied the waters. A recent investigation demon-
strated that the transcription factor Wilms’ tumor 1 (WT1)
increases the survival of glioblastoma cells in the presence
of cisplatin and carmustine. However, though silencing WT1
did increase sensitivity to the drugs, there was increased
IGF-1R expression as a result.76 These disparate conclusions
regarding IGF activity in glioma may be attributed to the
complex and seemingly independent mechanisms by which
resistance arises for different classes of drugs.IGFBP-2, which is overexpressed in nearly 80% of all
glioblastoma multiforme cases, appears to induce chemo-
resistance through an IGF-independent mechanism.77
Exogenous IGFBP-2 promotes proliferation and invasion of
several glioma lines, even in the presence of temozola-
mide. Immunofluorescence staining and in vitro knockdown
models show that this effect is mediated through activation
of integrin b1 and downstream phosphorylation and nuclear
translocation of ERK.78 Therefore, IGFBP-2 presents yet
another promising target for overcoming drug resistance
that may prove successful where direct IGF signaling in-
hibitors fall short. Ultimately, it will be necessary to iden-
tify reliable markers so as to determine not only the
primary mechanism by which resistance arises, but also to
predict the efficacy of IGF signaling inhibitors in novel
combination treatment regimens for glioma.Gastrointestinal cancers
Gastrointestinal (GI) neoplasms represent a significant
proportion of all new cancers diagnosed yearly, with prog-
nosis ranging from good to dismal based on the organs
involved and the extent of invasion.79e81 Gastric cancer
represents a form of malignancy with relatively poor out-
comes, in large part due to limited efficacy of chemo-
therapy. Studies have shown that drug resistance in these
cases is often associated with decreased expression of
microRNAs (miRs), small non-coding molecules that play a
key role in post-transcriptional regulation of genes by
repressing messenger RNA.82,83 In several cisplatin-resistant
gastric cancer lines, it appears that downregulated miR-503
is correlated with increased expression of IGF-1R and the
downstream anti-apoptotic Bcl-2 protein, as these genes
appear to be directly regulated by the microRNA. Further-
more, overexpression of miR-503 reduces the activity of
these proteins and subsequently re-sensitizes cells to
cisplatin-induced apoptosis.84 miR-1271 seems to play a
similar role in gastric cancer cells, restoring cisplatin
sensitivity in vitro by repressing IGF-1R, IRS-1, mTOR, and
Bcl-2.85 As such, these studies support a novel approach of
using microRNAs to modulate IGF signaling and perhaps
even overcome drug resistance.
Colorectal cancer (CRC) continues to be one of the most
aggressive malignancies with roughly a third of patients
succumbing to the disease within 5 years, despite recent
advances leading to earlier diagnosis and treatment.86 In
general, obesity has been associated with poorer outcomes
and may underlie drug resistance.87 One study looked at
the in vitro effects on CRC cells of low-dose oxaliplatin, 5-
fluorouracil, or irinotecan in combination with obesity-
related molecular phenomena, including elevated
glucose, insulin, and IGF-1.88 This was meant to emulate a
frequent situation in which obese patients are under-dosed
with chemotherapy.89 Though not always observed with
increased insulin or glucose concentrations, the combina-
tion of elevated IGF-1 and low-dose chemotherapy consis-
tently increased tumor cell survival.88 This data provides
intriguing insight into how IGF signaling may serve as a link
between obesity and development of drug resistance.
One of the mechanisms by which CRC cells are able to
develop multidrug resistance is through active efflux by
IGF signaling in cancer drug resistance 19pumps, such as multidrug-resistance-associated protein 2
(MRP-2), which can reduce intracellular drug concentra-
tion.90 IGF signaling has been thought to be involved with
this pump activity. In fact, IGF-1R silencing with specific
siRNA suppresses MRP-2 in CRC in vitro, thereby increasing
intracellular drug concentration of four types of anticancer
drugs separately. This effect appears to be mediated via
the PI3K/AKT pathway, which causes nuclear translocation
of nuclear factor-like 2 (Nrf2) and reduces expression of
MRP-2.91 This study presents yet another mechanism by
which resistance can arise, but offers the potential solution
that modulating IGF-1R activity can overcome this by
maintaining therapeutic drug levels inside target cells.
The role of IGF signaling is also apparent in hepatic and
pancreatic cancers resistant to treatment. HA22T, a hepa-
tocellular carcinoma (HCC) cell line resistant to the histone
deacetylase inhibitor apicidin, was found to display
increased levels of activated IGF-1R, PI3K, AKT, and Bcl-2.
Furthermore, the highly proliferative nature of these cells
could be attenuated by AKT knockdown.92 In addition, IGF
signaling seems to maintain the self-renewal capacity of
cancer stem cells (CSCs) within these tumors.93 In
oxaliplatin-resistant HCC, the stemness of a subpopulation
of tumor cells is associated with autocrine signaling of IGF-
1, whereas treatment with an IGF-1R inhibitor suppresses
CSC-related markers.94 In pancreatic cancer, IGF-1R
knockdown enhances the efficacy of gemcitabine in vitro,
likely due to inhibition of the downstream PI3K/AKT and
NF-kB activity.95 K-Ras, a GTPase belonging to the Ras
family, is frequently mutated into a constitutively active
form in pancreatic ductal adenocarcinoma (PDAC).96 This
mutation also confers resistance to experimental drugs
such as rapalog and everolimus, which are mTOR inhibitors,
by causing feedback activation of the IGF-1-Ras-ERK
pathway. In these cases, K-Ras knockdown blocks IGF-
induced ERK signaling and thereby enhances sensitivity to
everolimus.97 Furthermore, targeting IGF signaling may
offer another way to overcome drug resistance in tumors
identified to have a K-Ras mutation. Overall, there is clear
evidence that multiple GI malignancies can be made more
responsive to current therapy regimens by better under-
standing and working to modulate the underlying IGF
signaling abnormalities.Head and neck cancers
Head and neck cancers can have debilitating effects on
quality of life, often due to aggressive surgical resection at
the time of diagnosis.98,99 Despite these efforts, outcomes
still remain poor due to the dwindling response of tumors to
chemotherapy.100,101 IGF signaling remains under consid-
erable investigation for its contributions to this drug resis-
tance. In head and neck squamous cell cancer (HNSCC),
similar to lung cancer, EGFR-TKIs have had elicited poor
response in tumors, likely due to compensatory pro-survival
signaling caused by IGF-1R. In five HNSCC cell lines, IGF-1R
activation decreases apoptotic sensitivity to gefitinib
in vitro through downstream activation of AKT and ERK.102
Other studies have demonstrated that IRS-1 may be at the
root of this chemoresistance, showing that treatment with
gefitinib alters its binding and phosphorylation propertieswhich ultimately requires less IGF ligand for AKT activa-
tion.103 Keeping with these findings, direct IGF-1R inhibition
of HNSCC does indeed result in increased response to
treatment with EGFR antagonists.104 Furthermore, various
in vitro and in vivo studies have indicated that IGF signaling
blockade can augment the response to histone deacetylase
inhibitors, rapamycin, gemcitabine (a nucleoside analog),
and even radiation treatment by targeting similar resis-
tance mechanisms.105 It is clear that HNSCC represents yet
another disease for which IGF modulation may be a suitable
adjuvant therapy for overcoming drug resistance.
Bone and soft tissue tumors
Unique to most types of cancer, primary bone and soft tis-
sue tumors have a tendency to preferentially affect children
and adolescents. This is thought to be due to the underlying
mechanisms involved in both normal skeletal growth and
the development of these tumors, such as the extensively-
studied IGF pathway.1 In addition to contributing to the
malignant phenotype of bone diseases like osteosarcoma
(OS) and Ewing’s sarcoma, IGF signaling now appears to be
implicated in tumor response to pharmacologic agents.106
For example, IGF-1R inhibition has been shown to inhibit
OS proliferation and invasion while increasing sensitivity to
both radiation and chemotherapy with docetaxel, cisplatin,
or doxorubicin.107e110 Furthermore, IGFBP-5 is significantly
downregulated in OS, with overexpression of the N- and C-
terminal domains of the protein specifically inhibiting tumor
growth and invasion, respectively.16,17 These effects appear
to be mediated through both IGF-dependent and -indepen-
dent pathways, indicating a potential role for IGFBP-5 in
mono- or combination therapy to overcome various mech-
anisms of drug resistance.111
Rhabdomyosarcoma (RMS) is a soft tissue tumor of
muscle that also appears to be influenced by IGF
signaling.112 In addition to increased activity of IGF-1R,
downregulation of IGFBP-2 is associated with resistance of
RMS cells to therapy. Furthermore, it has been found that
resistance to IGF-1R inhibitors in vivo is actually mediated
by decreased IGFBP-2 through IGF-independent activation
of PI3K and mTOR.113 Another study found that IGF-2 mRNA
binding protein 1 (IGF2BP1) is implicated in driving trans-
lation of cellular inhibitor of apoptosis 1 (cIAP1), which
promotes resistance to tumor necrosis factor-alpha (TNFa).
Inhibiting cIAP1 through IAP antagonists or knockdown of
IGF2BP1 promotes sensitivity to TNFa, essentially by pre-
venting proliferative NF-kB signaling and allowing for cas-
pase-8-mediated cell death.114 It seems that studying
members of the IGF axis, even those that do not directly
mediate IGF-dependent signaling, offers various opportu-
nities for treating tumors that have become resistant to
both pre-existing and novel therapeutics.
Hematologic malignancies
Affecting patients of all ages, various cancers of the blood
and bone marrow are usually not amenable to surgical
treatment and unfortunately tend to show erratic response
to chemotherapy.115,116 Interestingly, though, downstream
components of the IGF signaling axis, including PI3K, AKT
20 S.K. Denduluri et al.and mTOR have been heavily implicated in conferring this
drug resistance.117e120 For example, in multiple myeloma,
IGF-1/IGF-1R activity is thought to reduce cell sensitivity to
bortezomib, a proteasome inhibitor. Exogenous IGF-1 is
shown to amplify this effect, whereas inhibiting IGF-1R
using small hairpin RNA increases the apoptotic effect of
the drug.121 In contrast, other studies have actually shown
that IGF-1 enhances the cytotoxic effect of proteasome
inhibitors, augmenting the effect of bortezomib on both
pro-apoptotic and anti-apoptotic protein levels.122 These
conflicting conclusions may be attributed to varying
experimental designs and use of different cell lines/tumors
in experiments. Regardless, the role of IGF in myeloma drug
resistance is quite intriguing and warrants further investi-
gation to develop novel therapies.
Patients with acute myeloid leukemia (AML) only have a
30e40% survival five years after diagnosis, most often due to
development of chemotherapy resistance.123 When studying
99 adult patients with AML found to be non-responsive to
cytarabine and anthracycline, one group found that high
IGFBP-2 mRNA levels are not only associated with, but pre-
dictive of, poor response to therapy due to upregulation of
genes involved in leukemogenesis.124 In addition, IGFBP-7
has been found to sensitize AML to cell death induced by
doxorubicin, etoposide, and cytarabine through an IGF-
independent mechanism of promoting G2 cell cycle ar-
rest.123 However, in acute lymphoblastic leukemia (ALL), an
opposite effect is seen as IGFBP-7 has been found to pro-
mote resistance to asparginase through interactions with
bone marrow stromal cells, even correlating with decreased
leukemia-free survival in patients.125 Overall, it seems that
molecular therapy targeting members of the IGF pathway
can one day be developed to enhance response to drugs
based on disease-specific mechanisms.
Conclusions and future directions
In conclusion, during a time when cancer treatment has
seemingly reached a plateau due to drug resistance, it is
critically important to not only understand the underlying
mechanisms of this phenomenon but also identify novel
therapeutic agents to overcome it. As evidenced by the
numerous studies reviewed above (summarized in Table 1),Table 1 Summary of IGF pathway members and their implicat
various human cancers.
IGF pathway
member
Observed or experimental
change
Confers resistance o
increases sensitivity?
IGF-1R ResistanceIGF signalingdemonstrates significantpromise inbothof these
aims. IGF-mediated effects, as well as IGF-independent
signaling by pathway-related molecules, are undoubtedly
involved in the response of various tumors to radio- and
chemotherapy regimens. Though an important element of
normal tissue growth and homeostasis, the IGF pathway ap-
pears just as important to cancer disease progression through
aberrant signaling. As discussed above, this dysregulation can
occur atmultiple levels, fromcrosstalkbetween IGFandother
hormone receptors to constitutive activation of downstream
proteins. What is most compelling is that members of this
pathway have the ability to promote (or reverse) resistance of
various cancer cells to many different classes of drugs (and
even radiotherapy) with unique mechanisms of action.
Therefore, it can be argued that the IGF axis should be one of
the most important foci of research efforts.
Previously, investigators have found the IGF pathway to
be implicated in the malignant phenotypes of various neo-
plasms, focusing their efforts on treating tumors with mod-
ulators of this pathway. Many potential drugs, such as IGF-1R
inhibitors, have now even made it to clinical trials, but the
outcomes of these studies have been largely under-
whelming.126 Used as monotherapy, these drugs may not
prove superior to current standard-of-care chemotherapy,
but there exists considerable potential for use of these
agents in combination therapy to improve existing treat-
ment regimens. In light of the compelling evidence pre-
sented here, future directions seem abundantly clear:
understand the effects of IGF signaling modulators in com-
bination with existing drugs in translational and clinical
studies. In addition, more emphasis needs to be placed on
studying members of the pathway that exert IGF-
independent effects, such as the IGFBPs. We cannot ignore
the possibility that such investigations might offer a wide
array of therapeutic benefits for drug-resistant tumors. In
parallel, researchers should seek to better understand how
dysregulation of IGF signaling occurs. This may eventually
help clinicians to prevent tumors from becoming not only
more aggressive, but also resistant to early therapy. Ulti-
mately, IGF signaling plays a remarkable role in the devel-
opment and progression of cancer despite therapy, so we
must seek to better control its properties if there are to be
substantial improvements in patient outcomes in the future.ions in promoting resistance or sensitivity to therapy among
r Affected cancer: Drug/Treatment
Breast ERþ: Tamoxifen22
Breast HER2þ: Trastuzumab28
Gastric: Cisplatin84
Glioma: Radiation,73 Temozolamide74
Hepatocellular: Apicidin92
HNSCC: Gefitinib102
NSCLC: Gefitinib,52 Erlotinib,55
Osteosarcoma: Radiation,108 Docetaxel, Cisplatin,107
Doxorubicin109,110
Ovarian: Cisplatin  taxol37
Prostate: Androgen deprivation therapy42
Table 1 (continued )
IGF pathway
member
Observed or experimental
change
Confers resistance or
increases sensitivity?
Affected cancer: Drug/Treatment
Sensitivity Colorectal: Multiple91
Gastric: Cisplatin84,85
Glioma: Radiation73
Hepatocellular: Oxaliplatin94
HNSCC: Methotrexate, Cetuximab,104 histone deacetylase
inhibitors, Rapamycin, Gemcitabine, Radiation105
Multiple myeloma: Bortezomib121
NSCLC: Gefitinib54
Ovarian: Platinum-based drugs39
Pancreatic: Gemcitabine95
Prostate: Androgen deprivation therapy42
IGF-1 Resistance Colorectal: Oxaliplatin, 5-Fluorouracil, Irinotecan88
Glioma: Tamoxifen75
Hepatocellular: Oxaliplatin94
Multiple myeloma: Bortezomib121
Pancreatic: Everolimus97
Sensitivity Multiple myeloma: Bortezomib122
IGF-2 Resistance Ovarian: Platinum-based drugs39
Sensitivity Ovarian: Taxol40
PI3K/AKT Resistance NSCLC: Gefitinib60
Sensitivity Glioma: Tamoxifen75
Hepatocellular: Apicidin92
NSCLC: Gefitinib60
Ras/ERK Resistance Pancreatic: Everolimus97
Sensitivity Pancreatic: Everolimus97
IGFBP-1 Resistance Prostate: Androgen deprivation therapy45
Sensitivity Prostate: Androgen deprivation therapy46,47
IGFBP-2 Resistance AML: Cytarabine, Anthracycline124
Glioma: Temozolamide78
NSCLC: Dasatinib62,63
Prostate: Docetaxel48
Sensitivity NSCLC: Dasatinib63
Prostate: Docetaxel48
Resistance RMS: IGF-1R antibody113
IGFBP-3 Resistance NSCLC: Gefitinib, Erlotinib,65 Cisplatin67
Sensitivity Breast ERþ: Fulvestrant27
NSCLC: Cisplatin68
(continued on next page)
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Table 1 (continued )
IGF pathway
member
Observed or experimental
change
Confers resistance or
increases sensitivity?
Affected cancer: Drug/Treatment
IGFBP-7 Resistance NSCLC: Cisplatin70
Sensitivity AML: Doxorubicin, Etoposide, Cytarabine123
NSCLC: Cisplatin70
Resistance ALL: Asparginase125
IGFBP-rP1 Sensitivity Prostate: Docetaxel, Radiation49
IGF2BP1 Resistance RMS: TNFa114
Sensitivity RMS: TNFa114
Abbreviations e ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ERþ: estrogen receptor positive; HNSCC: Head and
neck squamous cell cancer; IGF2BP1: insulin-like growth factor 2 mRNA binding protein 1; IGFBP-rP1: insulin-like growth factor binding
protein related peptide 1; NSCLC: Non-small cell lung cancer; RMS: rhabdomyosracoma
The upward arrows represent either upregulation, overexpression, or otherwise increased activity of the specific IGF pathway member
as observed or experimentally changed in the study. The downward arrows represent either downregulation, underexpression, or
otherwise decreased activity of the specified IGF pathway member.
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